Siemens Healthineers AG announces its results for the second quarter of fiscal year 2024 ended March 31, 2024.
Q2 Fiscal Year 2024
- Good equipment book-to-bill ratio of 1.08
- Comparable revenue growth of 3.0% against a very good prior-year quarter (excluding rapid COVID-19 antigen tests, growth of 11.7%)
- Imaging comparable revenue growth of 2.6% against significant growth in the prior-year quarter; adjusted EBIT margin of 20.2%
- Diagnostics comparable revenue growth of 3.7% (excluding rapid COVID-19 antigen tests 4.1%); adjusted EBIT margin 4.1%, clearly above the prior-year quarter
- Varian comparable revenue down slightly by 2.1% against the excellent prior-year quarter (growth of 27%); clear improvement in adjusted EBIT margin to 16.4%
- Advanced Therapies comparable revenue growth of 8.0% against very strong growth in the prior-year quarter; adjusted EBIT margin of 16.2%
- Overall adjusted EBIT margin of 15.1%
- Adjusted basic earnings per share of €0.55
Outlook for Fiscal Year 2024
We confirm our expectation of comparable revenue growth of between 4.5% and 6.5% (between 5.0% and 7.0% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of between €2.10 and €2.30.
Bernd Montag, CEO of Siemens Healthineers AG:
The Healthineers team has continued its successful growth trajectory, even relative to an excellent prior-year quarter. After an overall strong first half of the year, we are once again well on our way to achieving our targets for the financial year.
Source & Image Credit: Siemens Healthinears
Latest Articles
Siemens Healthineers, Q2 FY24 results, revenue growth, EBIT margin, fiscal year 2024
Siemens Healthineers AG Q2 FY24 results show 3.0% comparable revenue growth and a 15.1% adjusted EBIT margin. Strong performance outlook.
